Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.59
+0.46 (4.98%)
At close: Nov 22, 2024, 4:00 PM
9.64
+0.05 (0.57%)
After-hours: Nov 22, 2024, 6:11 PM EST
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 21.2, with a low estimate of 17 and a high estimate of 25. The average target predicts an increase of 121.18% from the current stock price of 9.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ZVRA stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +108.66% | Nov 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $23 | Strong Buy | Maintains | $25 → $23 | +139.96% | Nov 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +108.66% | Sep 30, 2024 |
Financial Forecast
Revenue This Year
23.88M
from 27.46M
Decreased by -13.04%
Revenue Next Year
99.93M
from 23.88M
Increased by 318.48%
EPS This Year
-1.70
from -1.30
EPS Next Year
-0.39
from -1.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 38.2M | 170.6M | 219.8M | ||
| Avg | 23.9M | 99.9M | 182.5M | ||
| Low | 17.4M | 46.5M | 145.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 39.2% | 614.6% | 120.0% | ||
| Avg | -13.0% | 318.5% | 82.6% | ||
| Low | -36.6% | 94.9% | 45.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.65 | 0.80 | 1.26 | ||
| Avg | -1.70 | -0.39 | 0.58 | ||
| Low | -1.71 | -1.24 | -0.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.